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Abstract
Background Sarcopenia is the loss of muscle mass/function that occurs during the aging process. The links between mech-
anistic target of rapamycin (mTOR) activity and muscle development are largely documented, but the role of its downstream
targets in the development of sarcopenia is poorly understood. Eukaryotic initiation factor 4E-binding proteins (4E-BPs) are
targets of mTOR that repress mRNA translation initiation and are involved in the control of several physiological processes.
However, their role in skeletal muscle is still poorly understood. The goal of this study was to assess how loss of 4E-BP1
and 4E-BP2 expression impacts skeletal muscle function and homeostasis in aged mice and to characterize the associated met-
abolic changes by metabolomic and lipidomic profiling.
Methods Twenty-four-month-old wild-type and whole body 4E-BP1/4E-BP2 double knockout (DKO) mice were used to mea-
sure muscle mass and function. Protein homeostasis was measured ex vivo in extensor digitorum longus by incorporation of L-
[U-14C]phenylalanine, and metabolomic and lipidomic profiling of skeletal muscle was performed by Metabolon, Inc.
Results The 4E-BP1/2 DKO mice exhibited an increase in muscle mass that was associated with increased grip strength
(P < 0.05). Protein synthesis was higher under both basal (+102%, P < 0.05) and stimulated conditions (+65%, P < 0.05) in
DKO skeletal muscle. Metabolomic and complex lipid analysis of skeletal muscle revealed robust differences pertaining to
amino acid homeostasis, carbohydrate abundance, and certain aspects of lipid metabolism. In particular, levels of most free
amino acids were lower within the 4E-BP1/2 DKO muscle. Interestingly, although glucose levels were unchanged, differences
were observed in the isobaric compound maltitol/lactitol (33-fold increase, P < 0.01) and in several additional carbohydrate
compounds. 4E-BP1/2 depletion also resulted in accumulation of medium-chain acylcarnitines and a 20% lower C2/C0
acylcarnitine ratio (P < 0.01) indicative of reduced β-oxidation.
Conclusions Taken together, these findings demonstrate that deletion of 4E-BPs is associated with perturbed energy metab-
olism in skeletal muscle and could have beneficial effects on skeletal muscle mass and function in aging mice. They also identify
4E-BPs as potential targets for the treatment of sarcopenia.
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Introduction
The mechanistic target of rapamycin (mTOR) is a central
regulator of cell growth and metabolism that responds to
a wide range of different stimuli including nutrient availabil-
ity, growth factors, and cellular energy status. In the last
two decades, extensive research has established mTOR as
a master regulator of many fundamental processes
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including protein synthesis and autophagy. Moreover, when
deregulated, it has been found to be associated with the
development of metabolic disorders such as obesity, type
2 diabetes, cancer progression, and the aging process (for
review, see Saxton and Sabatini1).
The eukaryotic translation initiation factor 4E-binding pro-
teins (4E-BPs) are a family of three proteins (4E-BP1, 2, and
3)2,3 that inhibit translation initiation by sequestering eIF4E.4
Their activity is controlled by the mTOR pathway. mTOR can
form two distinct complexes, mTOR complex 1 (mTORC1)
and mTOR complex 2 (mTORC2). Under nutrient or growth
factor deprivation, 4E-BPs are hypophosphorylated and inter-
act with eIF4E. In response to nutrients or growth factors, ac-
tivation of the mTORC1 leads to phosphorylation of the 4E-
BPs and their dissociation from eIF4E, ultimately resulting in
increased cap-dependent translation initiation.4,5 The physio-
logical role of 4E-BPs has been addressed in several studies.
4E-BP1 knockout (KO) mice display reduced adipose tissue
and increased energy expenditure.6 In contrast, deletion of
both 4E-BP1 and 4E-BP2 is associated with increased body
weight and increased sensitivity to diet-induced obesity and
insulin resistance.7,8 Finally, overexpression of 4E-BP1 is able
to protect mice from age-induced and diet-induced obesity
and insulin resistance.9,10 So far, only a few studies have ad-
dressed the role of the 4E-BPs in skeletal muscle function and
metabolism. In a recent study, Tsai et al. further analysed the
role of 4E-BP1 in skeletal muscle. They demonstrated that
muscle-specific transgenic overexpression of a constitutively
active form of 4E-BP1 protects mice from diet-induced obe-
sity. They also observed that activation of 4E-BP1 in skeletal
muscle results in muscle fibre transformation and enhanced
mitochondrial respiration.10 In response to diet-induced obe-
sity, we previously reported an increased ectopic accumula-
tion of lipotoxic species (diacylglycerols, ceramides, and
sphingomyelins) in skeletal muscle of mice lacking both 4E-
BP1 and 4E-BP2 associated with increased systemic insulin re-
sistance.8 Surprisingly, despite the development of a more se-
vere insulin resistance, 4E-BP1/2 double KO (DKO) mice
displayed an increased muscle mass in response to diet-
induced obesity, which suggests that 4E-BPs regulate muscle
homeostasis regardless of insulin sensitivity.8 Altogether,
these data demonstrate that 4E-BPs are key regulators of
muscle homeostasis and metabolism and play a critical role
in the development of insulin resistance and the accumula-
tion of ectopic lipids.
Aging is characterized by a progressive and involuntary
loss of skeletal muscle, termed sarcopenia, associated with
reduced muscle strength and exercise endurance.11,12
Sarcopenia is associated with a high risk of adverse out-
comes such as metabolic disorders, frailty, poor quality of
life, and death.13 Potential mechanisms contributing to
sarcopenia include inadequate or insufficient protein in-
take,14,15 a decline in the mitochondrial function,16,17 unbal-
anced protein turnover such as increased proteolysis18 and
reduced protein synthesis,19,20 and resistance to anabolic
signals (i.e. amino acids and insulin).21–23 Anabolic resistance
is associated with the ectopic accumulation of lipids in skel-
etal muscle, a process occurring frequently with age but also
favoured by obesity.24,25
Because 4E-BPs control translation initiation, a critical step
in the protein synthesis process, and regulate insulin sensitiv-
ity and the ectopic accumulation of lipotoxic compounds in
skeletal muscle, we hypothesized that deletion of 4E-BP1
and 4E-BP2 might protect mice from aging-associated loss
of muscle mass and function.
Materials and methods
Animals and experimental design
All breeding and experimental protocols were reviewed and
approved by the local ethics committee for animal experi-
mentation (CREFA Auvergne, agreement #00782.01) and
met the National Research Council’s guideline for the care
and use of laboratory animals. Congenic BALB/c
Eif4ebp1/ and Eif4ebp2/ (4E-BP1/2 DKO mice) as
previously described7 and BALB/c wild-type (WT) mice were
provided by Dr Nahum Sonenberg (McGill University, Mon-
tréal, Canada). Sixty-week-old male mice were individually
housed in plastic cages and maintained at 21–23°C with a
12 h dark–12 h light schedule, given free access to water
and food, and followed up to age 24 months. Mice were
fed a normal chow diet (25% protein, 61% carbohydrate,
and 14% fat; Safe-Diets, Augy, France). Twenty-four-
month-old mice were used for all the experiments in this
study. Euthanasia was performed at 10 a.m. after overnight
fasting during which mice had free access to water. Some
mice received an intraperitoneal injection of insulin
(1.2 mU/g body weight) 20 min before sacrifice. The geno-
type of each mouse was verified by PCR at birth and at the
end of the experiment.
Indirect calorimetric studies and whole body
composition analysis
Energy expenditure, volunteer home cage activity, and food
and water intake were measured by using a
PhenoMaster/LabMaster four-cage TSE system (Bad Hom-
burg, Germany). Spontaneous activity was measured using a
three-dimensional meshing of light beams. For whole body
composition analysis, mice were placed in an EchoMRI-100
analyser (Echo Medical Systems LLC, Houston, TX) to deter-
mine fat and lean body mass (g).
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Grip strength and wire screen holding tests
Grip strength and wire screen holding were measured as pre-
viously described.26 Briefly, grip strength was assessed using
a commercially available force gauge (Bioseb, Vitrolles,
France) by the same investigator. The apparatus consisted
of a metal grid connected to a force transducer. Each mouse
was held by the base of its tail and lowered towards the grid
of a grip strength meter and allowed to grasp it with its fore-
paws or both forepaws and hindpaws. The mouse was then
pulled steadily away from the rod by its tail until its grip
broke. Hindlimb grip strength in each mouse was measured
five times. For wire screen holding (hang test), each mouse
was placed on an aluminium mesh grid, which was then
inverted and held approximately 2 ft over a mouse cage con-
taining 2–3 in. of litter to avoid injury. The wire screen hold-
ing time is defined as the time elapsed before the mouse falls
from the inverted grid. The procedure was repeated three
times for each mouse with approximately 5 min between
each test. The physical impulse (Fdt) is the holding time (ht)
multiplied by the gravitational force of the mouse [Fdt
(N·s) = body mass (g) × 0.00980665 N/g × ht (s)] and repre-
sents the minimal total sustained force exerted to oppose
the gravitational force.
Ex vivo protein synthesis and proteolysis
measurement
Protein synthesis and degradation were measured as previ-
ously described.27 Briefly, mouse extensor digitorum longus
(EDL) muscles were preincubated for 30 min in Krebs–
Henseleit buffer (KHB) (120 mM NaCl, 4.8 mM KCl,
25 mM NaHCO3, 2.5 mM CaCl2, 1.2 mM KH2PO4, and
1.2 mM MgSO4; pH 7.4), supplemented with 5 mM HEPES,
5 mM glucose, and 0.1% bovine serum albumin (BSA) and
saturated with a 95% O2–5% CO2 gas mixture. Muscles
were then transferred into fresh media of the same com-
position containing 200 μM leucine, 5 mM insulin, and
500 μM L-[U-14C]phenylalanine (0.5 μCi/mL) for 60 min.
At the end of the incubation, muscles were quickly rinsed
in KHB, blotted, and homogenized in 10% trichloroacetic
acid (TCA). TCA insoluble material was washed three times
with 10% TCA and solubilized in 1 N NaOH at 37°C for de-
termination of protein-bound radioactivity and protein con-
tent. For protein degradation, muscles were incubated as
described earlier. Because tyrosine is neither synthesized
nor degraded by muscle, the release of this amino acid
from EDL muscle in the incubation medium reflects net
proteolysis. Tyrosine was measured by fluorometry.28 Pro-
tein breakdown was calculated as the sum of net protein
breakdown and protein synthesis, after converting the rate
of phenylalanine incorporation in proteins into tyrosine
equivalents.29
Chemicals
Protease inhibitor cocktail, primers, and the antibody against
P38 were purchased from Sigma-Aldrich (Saint-Quentin-
Fallavier, France); antibodies against 4E-BP1, Akt, Ser473-
phosphorylated Akt, S6K, and Thr389-phosphorylated S6K
were from Cell Signaling Technology; horseradish
peroxidase-conjugated secondary antibodies were from
DAKO (Trappes, France); SuperScript® III reverse transcrip-
tase, random hexamer, and oligo-dT primers were from
Invitrogen (Life Technologies, Saint-Aubin, France); Tri re-
agent was from Euromedex (Mundolsheim, France); and
Rotor-Gene SYBR Green PCR Master Mix from Qiagen
(Courtaboeuf, France).
Western blot analysis
Quadriceps were harvested in lysis buffer containing 50 mM
HEPES pH 7.4, 150 mM NaCl, 10 mM EDTA, 10 mM NaPPi,
25 mM β-glycerophosphate, 100 mM NaF, 2 mM Na
orthovanadate, 10% glycerol, 1% Triton X-100 containing 1%
of protease inhibitor cocktail (Sigma-Aldrich, Saint-Quentin-
Fallavier, France). Homogenates were centrifuged at
13 000 g for 10 min at 4°C. Denatured proteins were sepa-
rated by SDS–PAGE and transferred to a PVDF membrane
(Millipore, Molsheim, France). Immunoblots were blocked
with TBS-Tween-20 0.1% containing 5% dry milk and then
probed overnight at 4°C with primary antibodies. After sev-
eral washes with TBS-Tween-20 0.1%, immunoblots were in-
cubated with a horseradish peroxidase-conjugated
secondary antibody (DAKO, Trappes, France) for 1 h at room
temperature. The immune reactive strips or whole lanes were
visualized by chemiluminescence (ECL Western Blotting Sub-
strate, Thermo Fisher Scientific, Courtaboeuf, France). Lumi-
nescent secondary antibodies were visualized using an MF
ChemiBis 2.0 camera (Fusion Solo, Vilber Lourmat, France).
Band densities were quantified using MultiGauge 3.2 soft-
ware (Fujifilm Corporation, distributor FSVT, Courbevoie,
France). An internal control was used on each gel to normal-
ize signal intensities between gels.
RNA extraction and quantitative real-time PCR
Total RNA was extracted from frozen quadriceps using TRIzol
reagent (Invitrogen) according to the manufacturer’s instruc-
tions. RNA was quantified by measuring optical density at
260 nm. The concentrations of the mRNAs corresponding to
the genes of interest were measured by reverse transcription
followed by real-time PCR using a Rotor-Gene Q (Qiagen) sys-
tem. One microgram of total RNA was reverse transcribed
using SuperScript® III reverse transcriptase and a combination
of random hexamer and oligo-dT primers (Invitrogen). PCR
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amplification was performed in a 20 μL total reaction volume.
The RT–PCR mixture contained 5 μL of diluted cDNA tem-
plate, 10 μL of 2× Rotor-Gene SYBR Green PCR Master Mix,
and 0.5 μM of forward and reverse primers. The amplification
profile was initiated by 5 min incubation at 95°C to activate
HotStarTaq Plus DNA Polymerase, followed by 40 cycles of
two steps: 95°C for 5 s (denaturation step) and 60°C for
10 s (annealing/extension step). Relative mRNA concentra-
tions were analysed using Rotor-Gene software. The relative
abundance of mRNAs was calculated using the 2ΔΔCT
method with 36Β4 as housekeeping gene. The primers used
in the PCR are described in Table 1.
Metabolomic analysis
Six samples per experimental group from overnight-fasted
WT and 4E-BP1/2 DKO mice were included in the
metabolomic analysis of quadriceps. Metabolomic and com-
plex lipid profiling was performed by Metabolon (Morrisville,
NC); detailed methods are provided in the Supporting
Information.
Statistical analysis
Data are expressed as mean ± SEM. Differences between
groups were analysed with two-way analysis of variance,
and Bonferroni post-tests were used to compare replicate
means. Differences between groups on a per-metabolite ba-
sis were analysed with Welch’s two-sample t-test. A p value
of <0.05 was considered statistically significant.
Results
Muscle mass
In a previous study, we observed that hindlimb muscle
mass was slightly higher in 5-month-old 4E-BP1/2 DKO mice
fed a regular diet than in WT mice.8 Because aging is asso-
ciated with loss of muscle mass (sarcopenia), we measured
body composition by EchoMRI and the mass of several
hindlimb muscles of 24-month-old WT and 4E-BP1/2 DKO
mice. As previously described,7,8 we observed that 4E-
BP1/2 DKO mice weighed significantly more than did the
WT mice (Table 2). Food intake (5.12 ± 0.09 vs.
4.98 ± 0.08 g/day, NS) and energy expenditure
(39.2 ± 1.3 vs. 42.3 ± 1.0 kJ/day, NS) were similar in WT
and 4E-BP1/2 DKO mice, respectively. Overnight-fasted glu-
cose (2.03 ± 0.17 and 2.13 ± 0.05 g/L in WT and DKO, re-
spectively) and insulin (0.31 ± 0.03 and 0.37 ± 0.05 ng/mL
in WT and DKO, respectively) levels were unchanged in
the WT and 4E-BP1/2 DKO mice. EchoMRI revealed that
the difference in body weight was mainly attributable to
an increase in lean mass in the 4E-BP1/2 DKO mice as
the amount of fat mass was similar between the WT and
4E-BP1/2 DKO mice (Table 2). Several tissues were col-
lected and weighed after sacrifice to further characterize
this phenotype. No statistical difference was observed in
weight for the adipose tissues (gonadal and subcutaneous),
heart, or liver between the WT and 4E-BP1/2 DKO mice.
However, analysis of the hindlimb muscle revealed an in-
crease in the weight of all the muscle collected from 4E-
BP1/2 DKO mice compared with WT mice (Table 2,
P < 0.01).
Table 1. Primer sequences
Gene
Primers 50–30
Forward Reverse
36B4 ACTGGTCTAGGACCCGAGAAG TCCCACCTTGTCTCCAGTCT
Atg5 TCAACCGGAAACTCATGGAA CGGAACAGCTTCTGGATGAA
Bcat2 GCAGCCACACTAGGACAGGT ACACATCTTTTGGACCCACAT
Bckdha CTTGGAGCGCACAGACCT GGTAGTCCCGGTACATGAGC
Bckdhb CCCTTGTCTCAGGCTGAAGT TCCCGGATGACATGAACC
Cd36 TTGTACCTATACTGTGGCTAAATGAGA CTTGTGTTTTGAACATTTCTGCTT
Cpt1b TGGGACTGGTCGATTGCATC TCAGGGTTTGTCGGAAGAAGAA
Ctsl CAAATAAGAATAAATATTGGCTTGTCA TGTAGCCTTCCATACCCCATT
Dbt ACCGGAAGTAGCCATTGGT AAACGTCTCCTTTCTGGTCAAA
Dld GGGAGCACATATTCTAGGACCA TCACAGGAAGCACCATATTCC
Fatp1 TTCTCGGAGTCTGGAATGCT CACAGAGGCTGTTCCTGCTC
Lpl TCTAAATCCCACGAGCCCTA TTGAACCAAGCAGGTCACAG
MAFbx AAGCTTGTGCGATGTTACCCA CACGGATGGTCAGTGCCCTT
MCAD TTTCGGAGGCTATGGATTCAACAC TCAATGTGCTCACGAGCTATGATC
MuRF1 AGGTGTCAGGGCAAACAGT CCTCCTTTGTCCTCTTGCTG
Lat1 ATGGAGTGTGGCATTGGCTTC AGCACCGTCACAGAGAAGATA
Lat2 GACATCGGCCTCGTTGCT TGTAAGGATCCACAAGTTCCTCAGT
Snat1 CGAACCAGGACGGAGATAAAGG TCGTAGATGACCAGAGGGATGC
Snat2 CTCACTTACTGTGTCCCACA AACACGGTAGGCAGGCGGAT
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Muscle function
We measured voluntary locomotor activity in calorimetric
cages during the light and dark phases, and we performed sev-
eral mechanical tests to evaluate the muscle function of 24-
month-old WT and 4E-BP1/2 DKO mice. We did not observe
any difference in travelled distance between WT and 4E-BP1/
2 DKO mice regardless of the time of the day (Figure 1A). We
further analysed voluntary activity bymeasuring the timemice
were standing. Both genotypes spent more time standing in
the dark phase than in the light phase (Figure 1A). However,
despite the fact that the WT and 4E-BP1/2 DKO mice ran the
same distance, the 4E-BP1/2 DKO mice spent about twice as
much time standing than did WT mice in both the light and
dark phases (Figure 1B). To have a direct measurement of
muscle function, we performed a grip strength test (to mea-
sure the strength of the forelimbs alone or fore-
limbs + hindlimbs) and a hang test (physical impulse, which
measures the time during which a mouse opposes the gravita-
tional force associated with body mass). We did not observe
any difference in physical impulse between the WT and 4E-
BP1/2 DKO mice (Figure 1E). Both mean (≈+50%, P < 0.01)
and maximum grip strength (≈+35%, P < 0.01) were higher
in 4E-BP1/2 DKO mice than in WT mice (Figure 1C and D).
Extensor digitorum longus protein turnover
Because 4E-BPs are involved in the control of translation ini-
tiation, a critical step in the process of protein synthesis, pro-
tein turnover was measured in EDL muscle of WT and 4E-
BP1/2 DKO mice. Ex vivo stimulation of EDL by leucine and in-
sulin led to genotype differences. In WT EDL, stimulation of
protein synthesis by incubation with leucine and insulin
induced a ≈50% increase in L-[U-14C]phenylalanine incorpora-
tion (Figure 2A, P < 0.05). In EDL from 4E-BP1/2 DKO mice,
this stimulation led to a ≈25% increase in L-[U-14C]phenylala-
nine incorporation (P < 0.05), but its incorporation was ≈2-
fold higher under both basal and leucine/insulin-stimulated
conditions than in WT mice (Figure 2A, P < 0.05). In response
to insulin injection, phosphorylation of Akt on Ser473 and of
S6K1 on Thr389 was increased in both WT and 4E-BP1/2
DKO muscles, with there being no statistical significance
based on genotype (Figure 2B).
We then measured protein breakdown from the release of
tyrosine in the incubation medium as described in the incuba-
tion medium as described in materials and methods. Under
basal conditions, tyrosine release was reduced by ≈20% in
EDL from 4E-BP1/2 DKO mice compared with WT mice
(2.73 ± 0.12 vs. 3.38 ± 0.48 nmol/μg prot/h, Figure 2C, NS). In-
cubation with leucine/insulin led to a similar ≈20% decrease in
tyrosine release in EDL from both the 4E-BP1/2 DKO and WT
mice (2.11 ± 0.52 and 2.79 ± 0.49 nmol/μg prot/h, respec-
tively, Figure 2C, NS). The expression level of some proteolytic
system mRNA (MuRF1, Atrogin/MAFbx, Cathepsin L, ATG5)
was not affected by the deletion of the 4E-BPs (Figure 2D).
These changes in protein synthesis and degradation could ex-
plain the increased muscle mass in 4E-BP1/2 DKO male mice.
Global metabolomics and complex lipid profile of
skeletal muscle
To further analyse the metabolic alterations underpinning the in-
creased muscle mass and improved function in the 4E-BP1/2
DKO mice, we performed metabolomic and lipid profile analysis
on quadriceps derived from overnight-fasted WT and 4E-BP1/2
DKO mice (n = 6 per group). We detected 548 and 939 biochem-
icals in the metabolomic and complex lipid analyses, respectively,
of which 496 and 435matched known chemical structures in the
Metabolon chemical reference library. A summary of the num-
bers of biochemicals reaching statistical significance (P ≤ 0.05),
and of those approaching significance (0.05 < P < 0.10), is
shown in the Supporting Information (Figure S1).
Amino acid metabolism in skeletal muscle
When comparisons were made between the DKO and WT
groups, we observed that global free amino acid abundance
tended to be lower in 4E-BP1/2 DKO muscle (Figure 3A), with
significant reductions being present in non-essential (i.e. gluta-
mine, cysteine, arginine, and proline, P < 0.05) as well as es-
sential amino acids (i.e. threonine, phenylalanine,
tryptophan, and valine, P< 0.05). We also observed a 37% de-
crease in 3-methylhistidine (Figure 3A, P = 0.072), an indicator
of skeletal muscle protein breakdown30 in the 4E-BP1/2 DKO
muscle. In addition, the intracellular content of several
Table 2. Hindlimb skeletal muscle and tissue weight in WT and 4E-BP1/2
DKO mice
WT (n = 7) DKO (n = 9)
Weight (g) 26.8 ± 0.6 29.7 ± 0.7*
Lean mass (g) 22.8 ± 0.4 26.1 ± 0.7*
Fat mass (g) 2.42 ± 0.28 2.63 ± 0.26
Gastrocnemius (mg) 99.3 ± 4.8 119.0 ± 3.4*
Soleus (mg) 7.3 ± 0.3 10.2 ± 0.4*
Tibialis (mg) 42.5 ± 2.4 52.6 ± 1.4**
Plantaris (mg) 14.1 ± 0.5 17.1 ± 0.5*
Quadriceps (mg) 163.7 ± 6.0 195.7 ± 3.8**
EDL (mg) 13.5 ± 0.9 14.1 ± 0.5*
All muscles (mg) 340.4 ± 9.4 409.1 ± 6.7**
GWAT (mg) 217.3 ± 38.6 211.6 ± 30.9
SWAT (mg) 233.9 ± 46.2 234.2 ± 36.6
Liver (mg) 1160 ± 21 1328 ± 28
Heart (mg) 181.4 ± 8.4 205.6 ± 9.1
Mice were 24 months old. Results are expressed as mean ± SEM. p
values were assessed using unpaired t-test.
GWAT, gonadal white adipose tissue; SWAT, subcutaneous white
adipose tissue.
*P < 0.05.
**P < 0.01 vs. WT.
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dipeptides, which are incomplete breakdown products of pro-
tein catabolism, was also significantly reduced in 4E-BP1/2
DKOmuscle (Figure S2). To address whether amino acid trans-
port was modified by the deletion of the 4E-BP1 and 4E-BP2,
we measured mRNA levels of L-type amino acid transporters
(LAT1 and 2) and sodium-coupled neutral amino acid trans-
porters (SNAT1 and 2). Expression levels of LAT1, LAT2, SNAT1,
and SNAT2 were unaffected within the 4E-BP1/2 DKO muscle
(Figure 3B). To understand whether amino acid catabolism
was altered in 4E-BP1/2 DKO muscle, mRNA levels of genes
involved in branched-chain amino acid catabolism (BCAT2,
BCKDHA, BCKDHB, DBT, and DLD) were measured. mRNA
levels of these genes, likewise, were also unaltered in the 4E-
BP1/2 DKO muscle (Figure 3C).
Carbohydrate metabolism in skeletal muscle
Several carbohydrates were found to differ across the WT and
4E-BP1/2 DKO muscles (Figure S3). Although glucose levels
Figure 1 Spontaneous locomotor activity and muscle function in WT and 4E-BP1/2 DKO mice. Spontaneous locomotor activity in WT and 4E-BP1/2
DKO was measured using infrared sensor pairs arranged in strips for horizontal (A) and vertical (B) activities. Front forearm mean (C) and maximal
(D) grip strength in WT and 4E-BP1/2 DKO mice. (E) Mean holding impulse in the four limb wire grid holding test in WT and 4E-BP1/2 DKO mice.
n = 5–6 in each genotype, p values were assessed by two-way analysis of variance, and Bonferroni post-tests were used to compare replicate means
by row (in A and B) or by unpaired t-test (in C–E). ♦P < 0.05 vs. day, ♦♦P < 0.01 vs. day, * P < 0.05 vs. WT, ** P < 0.01 vs. WT.
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were unchanged between WT and 4E-BP1/2 DKO muscles,
there were appreciable differences in select metabolites
reporting on glycolysis and sugar metabolism. We observed a
52% reduction in glucose 6-phosphate levels (P < 0.05) and a
slight decrease in lactate (P = 0.08). In addition, compared with
WTmuscle, the 4E-BP1/2DKOmuscle also exhibited decreases
in the levels of galactose 1-phosphate (47%, P < 0.05),
galacticol (14%, P < 0.05), and mannose 6-phosphate
(P < 0.05). Only minor changes in the TCA cycle were ob-
served, with citrate (+14%, P = 0.07) and aconitate (+21%,
P = 0.07) being slightly elevated. Lastly, we observed a 33-fold
increase in the accumulation of sugar alcohols (maltitol/
lactitol/cellobiotol/palatinol, P < 0.001) in the 4E-BP1/2 DKO
muscle. This compound is isobaric in nature in that we cannot
distinguish between maltitol/lactitol/cellobiotol/palatinol on
the basis of their mass spectrometry signatures. Therefore,
this measurement can be contributed by one or all the above
sugars. Altogether, these changes may suggest potential
changes in carbohydrate intake and utilization in muscle.
Fatty acid metabolism
The sum of free fatty acid, diacylglycerol, and triacylglycerol
contents was unchanged between the WT and 4E-BP1/2 DKO
muscles. However, compared with WT muscle, the 4E-BP1/2
DKO muscle showed increased levels of several diacylglycerol
and triacylglycerol species (Figure S4) and a specific increase
in polyunsaturated free fatty acid (PUFA) content (Figure 4A)
as exemplified by the increases observed in arachidonic acid
(Free Fatty Acid (FFA) 20:4, +87%, P< 0.05), docosapentaenoic
acid (FFA 22:5, +44%, P < 0.05), and docosahexaenoic acid
(FFA 22:6, +34%, P < 0.05). mRNA expression levels of CD36,
FATP1, and LPL, involved in fatty acid transport, were un-
changed in 4E-BP1/2 DKO muscle compared with WT muscle
(Figure 4B). Despite unchanged carnitine levels, 4E-BP1/2
DKO muscle showed increased levels of several short-chain
and medium-chain acylcarnitines (Figure 5A). We observed
an accumulation of C5, C6, C8, and C10 species and a reduced
C2 (acetylcarnitine) to carnitine ratio (Figure 5B), indicative of a
Figure 2 Loss of 4E-BP1 and 4E-BP2 alters protein homeostasis in skeletal muscle. (A) Protein synthesis in WT and 4E-BP1/2 DKO skeletal muscles.
Protein synthesis was measured ex vivo by radioactive phenylalanine incorporation in extensor digitorum longus with (stimulated) or without (basal)
stimulation with a mixture of leucine and insulin. (B) Representative western blot levels of Akt, S6K, and 4E-BP1 phosphorylation in WT and 4E-BP1/2
DKO quadriceps. Mice were fasted overnight before receiving a 1.2 mU/g body weight intraperitoneal insulin injection. Mice were sacrificed 20 min
later, and tissues were collected for western blot analysis. (C) Proteolysis in WT and 4E-BP1/2 DKO skeletal muscles. Proteolysis was analysed
ex vivo in extensor digitorum longus by measuring tyrosine release as described in the materials and methods . (D) Real-time PCR quantification of
Atrogin/MAFbx, Cathepsin L, MuRF1, and ATG5 mRNA expression in quadriceps from WT and 4E-BP1/2 DKO mice. n = 5–6 in each genotype, p values
were assessed by two-way analysis of variance, and Bonferroni post-tests were used to compare replicate means by row (in A–C) or by unpaired t-test
(in D). ♦P < 0.05 vs. basal, * P < 0.05 vs. WT.
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lower rate of β-oxidation.31 The 4E-BP1/2 DKO mice demon-
strated a significantly higher respiratory quotient (calculated
as the ratio of VO2 to carbon dioxide production) than did
the WT mice (0.863 ± 0.018 vs. 0.808 ± 0.013, respectively,
P < 0.05, Figure 5D), which also indicate a reduced utilization
of fat as fuel source. No differences in any of the long-chain
acylcarnitine species were noted between the WT and 4E-
BP1/2 DKO muscles (Figure 5A). mRNA expression level of
CPT1B was unchanged, whereas MCAD mRNA level was re-
duced by ≈30% (P < 0.05) in 4E-BP1/2 DKO muscle compared
with WT muscle (Figure 5C).
Discussion
Aging is characterized by a progressive loss of physiological
functions with particular changes in the locomotor apparatus.
Impairment of the musculoskeletal system is characterized by
loss of muscle mass and function, commonly known as
sarcopenia.13 The pathophysiology of sarcopenia is complex
and, amongst other phenomena, involves increased muscle
proteolysis,18 reduced muscle protein synthesis,19,20,32 and
resistance to anabolic stimuli including insulin and amino
acids.21,23,33 In the present study, we demonstrate that dele-
tion of the 4E-BP1 and 4E-BP2 is associated with increased
muscle mass and function as well as protein synthesis in 24-
month-old mice. Global metabolomic and complex lipid anal-
ysis of WT and 4E-BP1/2 DKO skeletal muscle revealed robust
differences in amino acid homeostasis, carbohydrate abun-
dance, and certain aspects of lipid metabolism.
In previous studies, it was observed that deletion of 4E-BP1
and 4E-BP2 resulted in reduced energy expenditure,7,8
whereas energy expenditure is unaltered in the present study.
An important difference between these previous studies and
the current one is the age of the mice (24 vs. 6 months), and
this difference might in part explain the absence of modifica-
tion of energy expenditure we are observing. Indeed, in
humans, it is known that total energy expenditure is declining
from adulthood to old age.34,35 This decline is closely linked
with the decrease in whole body fat-free mass, which is com-
posed of metabolically active tissues, i.e. using a large part of
body energy.36 Amongst them, skeletal muscle is the main en-
ergy consuming tissue, and aging is associated with a loss of
Figure 3 Free amino acid content is reduced in 4E-BP1/2 DKO skeletal muscle. (A) Statistical heat map displaying the fold-change values observed
when amino acid abundances were compared between the WT and 4E-BP1/2 DKO quadriceps of 24-month-old mice. The dark green colour is used
to indicate statistically significant decreases P < 0.05, while the light green indicates differences that trended towards significance with a
0.05 < P < 0.1. (B) Real-time PCR quantification of amino acid transporter mRNA expression in quadriceps from WT and 4E-BP1/2 DKO 24-month-
old mice. (C) Real-time PCR quantification of mRNA expression of genes involved in branched-chain amino acid catabolism in quadriceps from WT
and 4E-BP1/2 DKO 24-month-old mice. n = 6 in each genotype.
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Figure 4 Loss of 4E-BP1 and 4E-BP2 induces accumulation of PUFA in skeletal muscle. (A) Statistical heat map displaying the fold-change values ob-
served when saturated, monounsaturated, and polyunsaturated free fatty acid abundance was compared between the quadriceps of 24-month-old
WT and 4E-BP1/2 DKO mice. The dark red colour is used to indicate statistically significant increases P < 0.05, while the light pink indicates differences
that trended towards significance with a 0.05 < P < 0.1. (B) Real-time PCR quantification of fatty acid transporters mRNA expression in quadriceps
from WT and 4E-BP1/2 DKO 24-month-old mice. n = 6 in each genotype.
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muscle mass, called sarcopenia. In a recent study,8 we mea-
sured muscle mass in 6-month-old mice. Total hindlimb skele-
tal mass was 418 ± 5 and 432 ± 3mg in WT and 4E-BP1/2 DKO
mice, respectively. Compared with the present results in 24-
month-old mice, i.e. 340 ± 9 and 409 ± 6 mg in WT and 4E-
BP1/2 DKO mice, respectively, we can observe that the
aging-associated loss of muscle is more pronounced in WT
(20%) than in 4E-BP1/2 DKO mice (6%). Therefore, the
maintained muscle mass observed in aged 4E-BP1/2 DKO
mice, as compared with WT mice, might have slowed down
the energy expenditure decline.
The link between mTOR activity and muscle development
is largely documented. Hyperactivation of mTORC1 by loss
of negative regulators, such as TSC1 or NPRL2, is able to in-
duce muscle hypertrophy.37,38 Conversely, muscle-specific in-
activation of mTOR leads to severe myopathy,39 and
inactivation of mTORC1 activity by deletion of Raptor or
S6K1 is able to prevent muscle growth and enhance atro-
phy.38,40 In a previous study, we observed that under high
fat diet feeding, despite the development of a more severe
insulin resistance, 4E-BP1/2 DKO adult mice showed in-
creased muscle mass.8 In the present study, using EDL mus-
cles, we observed that protein synthesis was increased
under basal conditions and after stimulation with a mix of
leucine and insulin in 4E-BP1/2 DKO mice. This result is in line
with previous results where global protein synthesis was
found to be increased in vitro in 4E-BP1/2 DKO
haematopoietic stem cells41 and primary fibroblasts.8 In an-
other study using 4E-BP1/2 DKO mice, Steiner et al. observed
that basal skeletal muscle protein synthesis was unchanged in
4E-BP1/2 DKO mice.42 The discrepancy between this last
study and ours is unclear but could be due to the different
Figure 5 Loss of 4E-BP1 and 4E-BP2 alters β-oxidation in skeletal muscle. (A) Statistical heat map displaying the fold-change values observed when
short-chain, medium-chain, and long-chain acylcarnitine abundance was compared between the quadriceps of 24-month-old WT and 4E-BP1/2 DKO
mice. The light pink indicates increases that trended towards significance with a 0.05 < P < 0.1. (B) Boxplots are shown for medium-chain
acylcarnitines and for the C2/carnitine ratio. (C) Real-time PCR quantification of CPT1b and MCAD mRNA expression in quadriceps from WT and 4E-
BP1/2 DKO 24-month-old mice. (D) Respiratory quotient calculated as the ratio of VO2 to carbon dioxide production in WT and 4E-BP1/2 DKO 24-
month-old mice. *P < 0.05 vs. WT, **P < 0.01 vs. WT. n = 6 in each genotype.
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models used. We measured protein synthesis ex vivo in 24-
month-old mice, whereas Steiner et al. measured it in vivo
in young mice. As impaired protein synthesis is known to be
associated with the development of sarcopenia, it is conceiv-
able that the increased protein synthesis we measured in 4E-
BP1/2 DKO muscle in aged mice reflects life-long maintained
protein synthesis in 4E-BP1/2 DKO mice compared with WT
mice in which aging induces a gradual decline in protein syn-
thesis. A longitudinal animal study designed to characterize
protein synthesis throughout the life course would be re-
quired to validate this hypothesis. In a recent study, Tsai
et al.10 demonstrated that the overexpression of a constitu-
tively active form of 4E-BP1 was associated with reduced run-
ning capacity on treadmill and reduced muscle fibre size. This
data are in agreement with the increased muscle strength
and suggestive of an increased muscle fibre size in aged 4E-
BP1/2 DKO mice. However, the increased muscle mass and
grip strength that we documented in aged 4E-BP1/2 DKO
mice are correlative in nature. No measures of muscle-
specific force production, muscle cross-sectional area, or
fibre-type composition are presented and would be required
to further understand the mechanisms responsible for this
muscle phenotype.
To further analyse the muscle changes associated with ag-
ing, we conducted global metabolomic profiling of WT and
4E-BP1/2 DKO quadriceps muscle derived from overnight-
fasted mice. This analysis revealed alterations in free amino
acid content, as well as in metabolites reporting on energy
metabolism. We observed an accumulation of polyunsatu-
rated free fatty acids in 4E-BP1/2 DKO muscle together with
increased levels of short-chain and medium-chain
acylcarnitines (Figure 5A and B). In skeletal muscle, fatty acid
synthesis is practically absent. Therefore, the increased poly-
unsaturated fatty acid content in 4E-BP1/2 DKO skeletal mus-
cle could be reflective of increased fatty acid uptake or
reduced β-oxidation. Short-term fasting, such as an overnight
fast, is known to increase lipolysis and β-oxidation43;
acylcarnitines are markers of mitochondrial lipid overload
and high rates of mitochondrial β-oxidation but are also indic-
ative of incomplete β-oxidation. In myotubes from donors
with high fasting respiratory quotient, the production and re-
lease of medium-chain acylcarnitines are higher, while the C2
(acetylcarnitine) to carnitine ratio, an index of β-oxidation,31
is lowered.44 The accumulation of C5–C10 acylcarnitines,
the lower C2/carnitine ratio in 4E-BP1/2 DKO muscle, and
the increased respiratory quotient of 4E-BP1/2 DKO mice
are consistent with such reduced β-oxidation capacity. CPT1B
is the rate-controlling enzyme in the long-chain fatty acid β-
oxidation pathway in muscle mitochondria, and MCAD is re-
sponsible for oxidizing C4 to C12 acyl-CoA. CPT1B mRNA level
was unchanged in 4E-BP1/2 DKO muscle, suggesting that
transport of fatty acids from the cytosol to the mitochondrial
matrix, where β-oxidation takes place, is unimpaired by the
deletion of 4E-BPs. The reason for the reduced expression
mRNA level of MCAD in 4E-BP1/2 DKO muscle is not clear,
but it may account for the increased accumulation of
medium-chain acylcarnitines and the reduced rate of β-
oxidation. In vitro, inhibition of mTORC1 with rapamycin stim-
ulates β-oxidation in L6 muscle cell line.45 Conversely, consti-
tutive activation of mTORC1 in mouse liver reduces the ability
of hepatocytes to stimulate β-oxidation in response to
fasting, whereas loss of raptor (mimicking an mTORC1 inacti-
vation) has the opposite effect.46 In liver, mTORC1 inhibits
the activity of PPARα, a key transcription factor in the regula-
tion of β-oxidation, by promoting the nuclear accumulation of
nuclear receptor corepressor 1 (NCoR1), which in turn inter-
acts with nuclear receptors to inhibit their activity. When ac-
tivated, mTORC1 favours the recruitment of NCoR1 to the
nucleus leading to inhibition of PPARα activity.47 These data
are in agreement with the reduction of β-oxidation that we
observed in 4E-BP1/2 DKO skeletal muscle of aged mice.
Whether this reduced β-oxidation is mediated by altered
PPARα activity and NCoR1 recruitment to the nucleus re-
mains to be studied.
In addition to their role in the control of translation initia-
tion, it was demonstrated that 4E-BPs are important media-
tors of mTORC1-dependent control of mitochondrial
biogenesis and function.48 Indeed, mTORC1 inhibition is asso-
ciated with impaired mitochondrial function, glycolysis (i.e.
intracellular accumulation of glucose and decreased levels
of pyruvate and lactate), and a significant decrease in several
TCA cycles intermediates (i.e. citrate, α-ketoglutarate, and
succinate) in MCF7 cells.48 Although mitochondrial respira-
tion is unaffected in 4E-BP-depleted untreated MCF7 cells,
loss of 4E-BPs relieves the effects of mTORC1 inhibition on
mitochondrial respiration, glycolysis, and Krebs cycle. In the
present study, mTORC1 activity was not inhibited by
rapamycin, and mitochondrial respiration was not measured
in skeletal muscle. However, we observed a slight reduction
in intracellular glucose and pyruvate and reduced levels of
lactate, which are suggestive of an increased glycolysis rate
in 4E-BP1/2 DKO skeletal muscle. We also observed a slight
increase in TCA cycle intermediates (i.e. citrate, isocitrate,
and aconitate). Altogether, these data are in agreement with
the 4E-BP-mediated role of mTORC1 in the control of glycol-
ysis and Krebs cycle.
Skeletal muscle content of almost all free amino acids was
reduced in the 4E-BP1/2 DKO mice. GATOR1 is a multi-protein
complex consisting of NPRL2, NPRL3, and DEPDC5, which in-
hibits mTORC1 activity during amino acid limitation.49,50 In a
recent study where NPRL2 was specifically deleted in skeletal
muscle (NPRL2mKO), Dutchak et al. showed that loss of NPRL2
and GATOR1 function in skeletal muscle induces constitutive
activation of mTORC1 and results in larger muscle fibres.37
Muscle deletion of NPRL2 induces aerobic glycolysis, sup-
presses glucose entry into the TCA cycle, and is associated with
reduced level of several amino acids. In that study, proteomic
analysis revealed increased abundance of enzymes required
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for glutamine and aspartate synthesis (precursors of purine
and pyrimidine synthesis) and a striking enrichment in proteins
involved in amino acid catabolism and fatty acid oxidation in
NPRL2 mKO soleus. These data indicate that activation of
mTORC1 promotes aerobic glycolysis and mitochondrial activ-
ity for biosynthetic purposes, such as synthesis of the non-
essential amino acids. This ultimately leads to a compensatory
response in the fatty acid and amino acid catabolism pathways
to replenish the TCA cycle intermediates for mitochondrial en-
ergy production.37 It is unlikely that reduction of free amino
acids in 4E-BP1/2 DKO muscle comes from a reduced amino
acid uptake from the blood, because food intake and mRNA
expression levels of several amino acid transporters in skeletal
muscle were similar between the WT and 4E-BP1/2 DKO mice
(Figure 3B). Furthermore, such a decrease in free amino acid
content was also observed in 4E-BP1/2 DKOMEFs in vitro (per-
sonal data). The increased protein synthesis we measured in
4E-BP1/2 DKO muscle may explain the decreased amino acid
content, but because protein synthesis is a process requiring
large amounts of energy, it is also conceivable that a significant
proportion of these amino acids is used as substrate to main-
tain energy production and compensate for the decreased β-
oxidation of fatty acids.
A limitation of our study was the use of a whole body KO
model for 4E-BP1 and 4E-BP2 deletion. Therefore, we cannot
exclude that some of the metabolic changes we documented
in skeletal muscles are indirect as changes in other tissues
may have an effect on muscle metabolism. Indeed, it is largely
documented that organ cross-talk is important to consider in
the control of physiological and metabolic processes. For ex-
ample, circulating lipids such as free fatty acids, from adipose
tissue and short-chain fatty acids from the gut, are able to
act on liver and skeletal muscle to regulate insulin sensitivity.51
In addition to these circulating factors, emerging evidence also
indicates that exosomes (small extracellular vesicles produced
by tissues) play a central role in the inter-organ dialogue by
transporting bioactive proteins, lipids, mRNAs, and miRNAs
that can be transferred to adjacent cells or to distant organs.52
Further experiments, usingmuscle-specific deletion ormuscle-
specific overexpression of 4E-BPs, will be required to fully
understand the role of these proteins in the maintenance of
muscle mass/function in aging.
In conclusion, we demonstrated that a deficiency of both
4E-BP1 and 4E-BP2 contributes to the maintenance of muscle
mass and function in aging through increased protein synthe-
sis. Through metabolomic and global lipid analysis, we also
demonstrated that 4E-BPs play a role in the control of energy
and amino acid metabolism in the skeletal muscle of 24-
month-old mice. Thus, 4E-BPs may be potential drug targets
in the treatment of sarcopenia.
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